US SEC Trading Suspension Halt Orders — October 16, 2026

16-10-2026

Aether Holdings, Inc. (Nasdaq: ATHR) received a Nasdaq Listing Qualifications notice on October 12, 2026 stating it no longer complies with Nasdaq Listing Rule 5620(a) because it did not hold an annual shareholder meeting within 12 months after its fiscal year ended September 30, 2025. The notice has no immediate effect on the listing or trading of the common stock, but the company must submit a compliance plan by November 27, 2026, and could receive an exception of up to 180 days (until March 29, 2027) if Nasdaq accepts the plan. Management intends to submit the plan and hold the meeting, but there is no assurance of acceptance or compliance.

• · Notice cites Nasdaq Listing Rule 5620(a) (annual meeting requirement) and Listing Rule 5810(c)(2)(G) for the compliance plan process
• · Notice is dated October 12, 2026, and the 8-K was filed October 16, 2026
• · Company is an emerging growth company, headquartered at 110 Charlton Street, New York, NY
• · Company has stated it intends to hold an annual meeting within the period Nasdaq permits

16-10-2026

SITE Centers Corp. (NYSE: SITC) notified the New York Stock Exchange on October 15, 2026 of its intention to voluntarily delist its common shares, acting under authority granted by its Board that became effective upon the sale of the company's interests in the Dividend Trust Portfolio joint venture. The company plans to file a Form 25 on November 23, 2026, with the de-listing expected to be effective before trading commences on December 4, 2026. This is a voluntary delisting, not a failure to meet a continued listing standard.

• · Form 25 filing targeted for November 23, 2026
• · Expected effective date of de-listing is prior to trading commencement on December 4, 2026
• · Delisting is voluntary and was authorized by the Board following the Dividend Trust Portfolio joint venture sale
• · Filing is under Item 3.01 but reflects a voluntary action, not a deficiency notice

16-10-2026

Callan JMB Inc. (Nasdaq: CJMB) received a Nasdaq Staff Determination on October 12, 2026 stating it failed to meet the terms of an extension to regain compliance with the $2,500,000 minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1), after being unable to complete its capital raising initiatives. Absent an appeal, trading would be suspended on October 21, 2026 and the common stock delisted. The Company requested a hearing before a Nasdaq Hearings Panel on October 14, 2026, which stays the suspension and delisting pending the Panel's decision, but there is no assurance the Panel will grant continued listing.

• · Staff initially issued a deficiency letter on April 7, 2026, and granted an extension to October 5, 2026 to regain compliance
• · Staff Determination received October 12, 2026; appeal deadline October 19, 2026
• · Scheduled trading suspension date absent appeal: October 21, 2026; Form 25-NSE to be filed with the SEC to remove securities from listing and registration
• · Hearing request filed under Nasdaq Rule 5815(a) on October 14, 2026, staying suspension and Form 25-NSE pending Panel decision
• · Company is an emerging growth company; common stock par value $0.001; ticker CJMB; principal offices in Spring Branch, Texas

16-10-2026

eHealth, Inc. received a written notice from Nasdaq on October 14, 2026 stating its common stock closed below the $1.00 minimum bid price for 30 consecutive business days, a breach of Nasdaq Listing Rule 5450(a)(1). The notice has no immediate effect on the listing, and the company has until April 12, 2027 (180 calendar days) to regain compliance by closing at or above $1.00 for at least 10 consecutive business days, which may involve seeking stockholder approval for a reverse stock split. The filing is negative in tone, as the company explicitly warns there is no assurance it will regain compliance.

• · Company may transfer to The Nasdaq Capital Market, if eligible, to obtain an additional 180-day compliance period
• · Nasdaq staff may exercise discretion to extend the 10-day requirement under Rule 5810(c)(3)(H)
• · Risk factors cited include failure to regain compliance, failure to meet other listing requirements, and possible unsuccessful appeal of any delisting determination

16-10-2026

Lucid Diagnostics received a Nasdaq Listing Qualifications notice on October 12, 2026 stating its common stock closed below the $1.00 minimum bid price for 30 consecutive business days through October 9, 2026, in breach of Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days, until April 12, 2027, to regain compliance by maintaining a closing bid of at least $1.00 for ten consecutive business days, with a possible additional 180-day period. The notice has no immediate effect on the listing, and LUCD continues trading uninterrupted on Nasdaq.

• · The company may be eligible for an additional 180-day compliance period if it does not regain compliance within the initial period, and otherwise Nasdaq will issue a delisting notice after the initial period ends.
• · Nasdaq listing rule cited: 5550(a)(2) for the Nasdaq Capital Market; the Company is an emerging growth company.

16-10-2026

Health In Tech, Inc. (Nasdaq: HIT) received two Nasdaq deficiency letters: (1) a non-compliance notice on Nasdaq's independent director and audit committee requirements (Rules 5605(b)(1) and 5605(c)(2)(A)) following the August 10, 2026 resignation of director Sanjay Shrestha from the Board and Audit Committee, with cure expected at the November 10, 2026 annual meeting; and (2) a notice that the Class A common stock has closed below the $1.00 minimum bid price for 30 consecutive business days, with a compliance deadline of April 12, 2027. Neither notice has an immediate effect on listing or trading, but the company faces a real risk of eventual delisting if the bid price is not regained.

• · Cure deadline for the independent director and audit committee deficiency is the earlier of the next annual meeting or August 10, 2027; if the annual meeting is held before February 8, 2027, compliance must be evidenced by February 8, 2027.
• · The company plans to elect a new independent director nominee at the November 10, 2026 annual meeting and appoint that person to the Audit Committee.
• · If the bid price deficiency is not cured by April 12, 2027, the company may qualify for an additional 180-day period only if it meets market value of publicly held shares and other initial listing standards (excluding bid price) and provides written notice of intent to cure, possibly via reverse stock split.
• · A reverse stock split, if used, must be completed no later than ten business days before April 12, 2027.
• · Failure to regain compliance could lead to a Nasdaq delisting notification, which the company could appeal.
• · The filing references the Company's Form 10-Q for the quarter ended June 30, 2026 (filed August 13, 2026) and Definitive Proxy Statement (filed October 13, 2026) as prior disclosures of the director resignation and cure plan.

16-10-2026

Bridgeline Digital, Inc. (Nasdaq: BLIN) received a Nasdaq notice on October 14, 2026 stating that its common stock closed below the $1.00 minimum bid price for 30 consecutive business days ended October 13, 2026, a deficiency under Nasdaq Listing Rule 5550(a)(2). The company has an initial 180-calendar-day compliance period, through April 12, 2027, to regain compliance by closing at or above $1.00 for at least 10 consecutive business days, with a possible additional 180-day period if it qualifies and provides written notice of intent to cure. The letter does not trigger immediate delisting from The Nasdaq Capital Market.

• · Nasdaq letter dated/received October 14, 2026; 8-K filed October 16, 2026
• · Company must also satisfy market value of publicly held shares and other initial listing standards (excluding bid price) to qualify for the additional period
• · Company must provide Nasdaq written notice of its intent to cure the deficiency to obtain the additional period
• · Company states it will monitor its bid price and consider available options if it cannot regain compliance

16-10-2026

Apollo Commercial Real Estate Finance, Inc. (NYSE: ARI) announced on October 16, 2026 that it intends to file a Form 25 with the SEC and NYSE to delist its common stock on or about October 27, 2026, with the last day of trading on the NYSE expected to be November 6, 2026. The filing does not state a reason for the delisting, and it contains no financial results or quantitative performance data.

• · Form 25 (Notification of Removal from Listing) expected to be filed on or about October 27, 2026
• · Last expected day of NYSE trading: November 6, 2026
• · Filing references Exhibit 99.1, a press release dated October 16, 2026, furnished under Item 7.01 (Regulation FD) and not deemed filed under Section 18 of the Exchange Act
• · The filing does not disclose the reason for the delisting

16-10-2026

Canopy Growth Corporation received a Nasdaq notice on October 14, 2026 for non-compliance with the $1.00 minimum bid price rule (Nasdaq Listing Rule 5450(a)(1)), after its shares closed below $1.00 for 30 consecutive business days. The company has until April 12, 2027 to regain compliance, with a possible second 180-day period if it transfers to the Nasdaq Capital Market; the letter has no immediate effect on trading, and the Toronto Stock Exchange listing is unaffected. The company's shareholder vote on a reverse stock split (1-for-5 to 1-for-15) is scheduled to reconvene on October 23, 2026, after the September 25, 2026 meeting was adjourned for lack of quorum, and management states there is no assurance of approval or of a sustained price increase.

• · Nasdaq letter dated October 14, 2026; the company must regain compliance by April 12, 2027
• · Any reverse split must be completed at least ten business days before the compliance period expires
• · Proposed reverse split ratio and the board's discretion to set it are valid through October 23, 2027
• · Shareholder meeting was adjourned September 25, 2026 for lack of quorum and reconvenes October 23, 2026
• · Company's Toronto Stock Exchange listing compliance is not affected by the Nasdaq notice